Physician profile
Vineet Dua
NPI 1447291216
$77,150.00
in general payments reported to CMS, 2019-2025
41 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $20K · 2021: $3,815 · 2022: $990 · 2023: $1,273 · 2024: $1,023 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,298 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,298.23 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $49,602.76 | 2019-2020 | |
| Boston Scientific Corporation | $12,538.78 | 2019-2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $9,596.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $589.35 | 2019-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $486.34 | 2023-2025 | Ffrct |
| Pfizer INC. | $468.52 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $437.96 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $429.15 | 2020-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $326.72 | 2019-2025 | Wainua, Farxiga |
| Janssen Pharmaceuticals, INC | $304.54 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $268.49 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $260.71 | 2022-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.15 | 2019-2023 | Jardiance |
| Kestra Medical Technology Services, INC. | $145.79 | 2022-2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $132.42 | 2020-2024 | Nexletol |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $129.01 | 2023-2025 | Barostim Neo System |
| Medtronic, INC. | $120.72 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.95 | 2019-2024 | Lifevest |
| Inspire Medical Systems, INC. | $116.94 | 2024 | Inspire |
| W. L. Gore & Associates, INC. | $104.71 | 2020-2021 | |
| Edwards Lifesciences Corporation | $99.51 | 2024 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $98.21 | 2021-2024 | |
| Cleerly, INC. | $66.20 | 2024 | Cleerly Labs |
| Lexicon Pharmaceuticals, INC. | $63.73 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $52.93 | 2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $52.63 | 2025 | Amvuttra |
| Bridgebio Pharma, INC. | $41.50 | 2025 | Attruby |
| Abiomed | $33.03 | 2023 | Impella |
| Imperative Care, INC | $33.00 | 2025 | Symphony Catheter |
| Scpharmaceuticals INC. | $32.38 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $31.51 | 2019 | |
| United Therapeutics Corporation | $30.45 | 2025 | Tyvaso |
| Atricure, INC. | $25.60 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Kiniksa Pharmaceuticals International, Plc | $23.12 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $21.29 | 2020 | |
| Siemens Medical Solutions USA, INC. | $19.00 | 2024 | Artis Icono Floor |
| Impulse Dynamics (USA) INC. | $16.96 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals, LTD. | $16.84 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $14.98 | 2024 | Opsumit, Uptravi |
| Arbor Pharmaceuticals, INC. | $11.94 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $7.23 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineet Dua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.